Elekta AB (OTCMKTS:EKTAY) Sees Large Increase in Short Interest

Elekta AB (OTCMKTS:EKTAY) was the target of a large increase in short interest in July. As of July 15th, there was short interest totaling 3,663 shares, an increase of 142.1% from the June 30th total of 1,513 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 9,213 shares, the short-interest ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Elekta Trading Up 0.5%

Shares of EKTAY stock opened at $4.99 on Thursday. Elekta has a 1 year low of $4.35 and a 1 year high of $6.93. The firm has a market capitalization of $1.84 billion, a PE ratio of -31.16 and a beta of 1.01. The stock has a fifty day moving average of $5.32 and a two-hundred day moving average of $5.86. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.68 and a current ratio of 0.87.

Elekta (OTCMKTS:EKTAY) last posted its quarterly earnings data on Thursday, May 28th. The company reported $0.06 EPS for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%.The company had revenue of $521.00 million for the quarter. As a group, research analysts expect that Elekta will post 0.43 EPS for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.